CTOR
Citius Oncology, Inc.NASDAQHEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC
Key Statistics
Market Cap
$77.67M
P/E Ratio
—
EPS
$-0.31
Beta
3.43
52W High
$6.19
52W Low
$0.49
50-Day MA
$0.84
200-Day MA
$1.35
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
35.59
PEG Ratio
—
About Citius Oncology, Inc.
Citius Oncology, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative cancer therapies for underserved patient populations. The company boasts a diverse pipeline of proprietary technologies aimed at enhancing treatment efficacy and safety across multiple cancer indications. By establishing strategic partnerships and adhering to stringent clinical research standards, Citius Oncology is positioned to advance its promising drug candidates through pivotal clinical trials and regulatory approvals, all while striving to significantly improve patient outcomes in the oncology landscape.
Fundamentals
| Revenue (TTM) | $3.94M |
| Gross Profit (TTM) | $3.15M |
| EBITDA | — |
| Operating Margin | -133.20% |
| Return on Equity | -47.40% |
| Return on Assets | -14.00% |
| Revenue/Share (TTM) | $0.05 |
| Book Value | $0.69 |
| Price-to-Book | 1.33 |
| Price-to-Sales (TTM) | 19.69 |
| EV/Revenue | 18.81 |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $88.28M |
| Float | $14.13M |
| % Insiders | 83.89% |
| % Institutions | 7.79% |
Historical Volatility
HV 10-Day
85.21%
HV 20-Day
86.54%
HV 30-Day
107.67%
HV 60-Day
89.51%
HV Rank
—
Volatility is currently contracting
Analyst Ratings
Consensus ($6.00 target)
1
Strong BuyData last updated: 5/1/2026